+1-888-308-5802     
News Contact Us

Australia approves Merck’s patent for use of paired CRISPR nickases

Author : Paroma Bhattacharya | Published Date : 2018-08-17 

Merck, the leading pharmaceutical and life science firm, has reportedly announced that it has availed permission for the patent application of paired CRISPR nickases from the Australian Patent Office. Sources claim that Merck's CRISPR integration patent portfolio already boasts of patents granted in Europe, Australia, China, Canada, South Korea, Israel, and Singapore.

According to trusted reports Merck’s IP would be required by commercial organizations for CRISPR-based DNA insertion if the firm needs access to the right defect in the somatic cells of the patient undergoing gene therapy. Merck plans to license this patent soon for various fields.

As per the granted patent application, two CRISPR nickases are targeted to one gene target that act by slashing the opposite strands of the chromosome series to generate a bi-stranded break.

Seeking Alpha reports Udit Batra CEO, Life Science, Merck KGaA to have stated that the allowance for this new patent represents a commendable advancement in CRISPR-enabled therapeutics safety. The paired nickase CRISPR technology is particularly important for the research community that requires extremely accurate methods during the development of treatment methodologies for difficult-to-treat diseases, he further affirms.

For the uninitiated, Merck was the first company that incepted custom biomolecules for genome editing across the globe (TargeTron™ RNA-guided group II introns & CompoZr™ zinc finger nucleases), motivating the overall R&D community to adopt this technique.

According to sources, the Australian Patent Office has not only approved the patent application for paired nickases but has also declared the grant for Merck's CRISPR integration 2017 patent after four anonymously filed petitions were withdrawn.

For the record, Merck KGaA is also the first company of its kind to have manufactured arrayed CRISPR libraries that reportedly cover the whole genome, allowing for a faster cure as scientists can precisely analyze the root cause of the disease.

About Author

Paroma Bhattacharya

Paroma Bhattacharya

Paroma Bhattacharya, having completed her post-graduation in Journalism and Mass Communication, started her career in writing with resourceful and informative content development across diverse fields. Having dealt in myriad topics ranging from business to real estate, she now pens down articles for fractovia.org and other portals. She can be contacted at- [email protected] | https://twitter.com/paromab1

Related News

Chinese GoPro rival Insta360 raises $30M as it moves towards 2020 IPO

Published Date: 2019-03-22         Author: Paroma Bhattacharya

The company’s Series C+ funding round saw participation from a number of Chinese investors including Huajin Capital, Everest Venture Capital & MC Holdings. The move comes as the company is on its way to go public through an IPO scheduled for launch in 2020. Shenzhen Arashi Vision... Read More

Five Point Fours collapse leaves thousands of people in the lurch

Published Date: 2019-03-18         Author: Paroma Bhattacharya

The company recently issued a notice of administration to the ASIC (Australian Securities & Investments Commission). Brisbane-based health food delivery company, Five Point Four, is reportedly going to close down, much to the surprise of its massive customer base and over 230,000 online follo... Read More

Mswipe secures Rs.220 crore in funds in Series E investment round

Published Date: 2019-03-16         Author: Paroma Bhattacharya

Mswipe Technologies Pvt. Ltd., a Mumbai-based PoS (Point-of-Sale) & business payment solutions provider, has grabbed headlines for receiving up to R. 220 crore in the latest Series E financing round. Reportedly, the leading investors participating in the round include the American hedge fund ... Read More

© 2019 Fractovia. All Rights Reserved